3 AI Healthcare Stocks Tackling Hospital Costs Investors May Want To Watch
UK inflation ticking up to 2.9% in July keeps the focus on cost control and productivity. That shines a light on AI healthcare stocks that aim to cut waste, speed diagnosis, and support overstretched systems. Investors looking for growth stories linked to real world problems may not want to ignore this theme. This article highlights three Transformative AI Healthcare Screener stocks that are currently worth watching.
The three stocks below are just a sample from this theme. The full Transformative AI Healthcare screen surfaced four more companies with equally compelling narratives that are not covered here. To go further, identify potential leaders, and analyze how they stack up, head straight into the Transformative Artificial intelligence (AI) Healthcare Stocks screener.
Profound Medical (TSX:PRN)
Overview: Profound Medical develops AI-powered, MRI-guided systems such as its TULSA-PRO platform, which uses image processing, robotically controlled ultrasound, and closed loop temperature feedback to precisely ablate prostate tissue without incisions. The company also sells the Sonalleve MRI-guided therapy system for conditions such as uterine fibroids and palliative pain, giving it a broader medical device footprint alongside its core AI-enabled interventional prostate treatment.
Operations: Profound Medical generates all of its roughly $19 million in revenue from medical technology, with about $12 million from the United States, $6 million from Canada, and under $1 million from Germany.
Market Cap: CA$357 million
Profound Medical is worth a closer look if you want direct exposure to AI-guided procedures rather than just diagnostic software. Its TULSA-PRO system applies real time MRI imaging, AI-style feedback control, and supervised robotic autonomy to aim for precise prostate tissue ablation. This approach could appeal to hospitals seeking better outcomes and more efficient theatre time. Recent CAPTAIN trial data and software upgrades that support more tailored treatments and potential telesurgery add to the story. At the same time, the company is still reporting losses and must manage adoption hurdles, regulatory complexity, and integration costs. If this AI hardware driven angle on prostate care gains wider acceptance, current investors may be getting in before the full implications are clear.
Profound Medical’s AI-guided procedures could be reshaping prostate care, yet the real debate is how its risks and rewards balance out. Get the full picture in the 1 key reward and 1 important warning sign
Build your own AI healthcare shortlist
Profound Medical and the two other AI healthcare stocks in this article all came from a single screen, but your best ideas often start with your own filters. Use our flexible Screener to combine metrics like valuation, growth, balance sheet strength, and risks, or jump straight into curated themes with our Investing Ideas.
Healwell AI (TSX:AIDX)
Overview: Healwell AI is a healthcare technology company that builds AI driven clinical decision support systems, diagnostic engines, and an EHR integrated co pilot to help doctors spot rare and chronic diseases earlier and tailor treatment using real world patient data. Alongside this AI and Data Sciences segment, it also runs a sizeable healthcare software business that supplies electronic health record platforms, interoperability tools, and services to providers, public health bodies, insurers, and life sciences clients in Canada, Australia, and New Zealand.
Operations: Healwell AI generates about CA$119 million from Healthcare Software and about CA$10 million from AI and Data Sciences, with roughly CA$110 million of total revenue from Australia and New Zealand and about CA$18 million from Canada.
Market Cap: CA$225 million
Healwell AI may appeal to investors who want direct exposure to AI tools embedded inside everyday clinical workflows rather than pure research projects. Its DARWEN powered engines sit inside existing electronic health record systems to support disease detection and produce auditable summaries, which aligns with efforts to develop safer, more efficient healthcare AI. At the same time, Healwell is still loss making and relies heavily on acquisitions and a shift toward higher margin software, so execution on integration and cross selling will be crucial. For investors who are comfortable with those risks, the combination of AI driven diagnostics, healthcare software scale, and an active product pipeline could warrant a closer look.
Healwell AI’s push to embed DARWEN into routine clinical workflows could be more powerful than the headline revenue split suggests. See how the story looks when you line up the analyst forecasts for Healwell AI and one potential spoiler risk
Perimeter Medical Imaging AI (TSXV:PINK)
Overview: Perimeter Medical Imaging AI develops optical coherence tomography imaging systems such as the S Series and Claire OCT. These systems give surgeons real time views of excised tissue margins during operations, with Claire’s ImgAssist AI specifically aimed at helping breast cancer surgeons assess margins more accurately in the operating room. The company also supports hospitals and cancer surgery centers with a proprietary image library and consumable specimen containers that sit around its imaging platform.
Operations: Perimeter Medical Imaging AI currently generates about $2.1 million in revenue from medical imaging systems, all from Canada.
Market Cap: CA$59.8 million
Perimeter Medical Imaging AI is closely tied to the AI diagnostics theme through its Claire OCT system with ImgAssist, which applies AI to real time margin assessment in breast conserving surgery and is already being deployed at Intermountain Health in the U.S. For investors, the appeal centers on a focused AI product tackling a specific surgical pain point, early commercial traction, supportive grants for next generation AI work, and a share price that sits well below one internal fair value estimate. At the same time, revenue is still only about $2 million, the company is unprofitable with funding and dilution risks, and execution on clinician uptake remains critical to the story.
Perimeter Medical Imaging AI is tackling a precise surgical problem with Claire’s ImgAssist AI, yet few investors seem to connect the focused product, early traction, and funding risks in one view. Get the full story and its key twists in the analysis report for Perimeter Medical Imaging AI
Seeking Alternatives Before The Crowd Moves
Fresh stock stories can gain momentum fast and you do not want to get caught chasing a breakout after it is already flying. Scan these under the radar ideas while it matters and act now.
- Spot companies building staying power in tough markets and run them through the list of solid balance sheet and fundamentals (12 results) before the rest of the crowd catches on.
- Hunt for steady income streams that keep paying even when sentiment drops by checking out the curated 4 dividend fortresses while yields still look attractive.
- Track where real AI revenue is already flowing and filter for focused operators with the targeted 75 profitable AI stocks that aren't just burning cash before momentum traders arrive.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com